# A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases

> **NCT06318533** · EARLY_PHASE1 · RECRUITING · sponsor: **YANRU WANG** · enrollment: 15 (estimated)

## Conditions studied

- Autoimmune Diseases

## Interventions

- **DRUG:** anti-CD19 CAR NK cells

## Key facts

- **NCT ID:** NCT06318533
- **Lead sponsor:** YANRU WANG
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-13
- **Primary completion:** 2026-03-13
- **Final completion:** 2027-03-13
- **Target enrollment:** 15 (ESTIMATED)
- **Last updated:** 2025-05-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06318533

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06318533, "A Clinical Study of CD19 CAR NK Cells for the Treatment of Relapsed/Refractory B-cell Related Autoimmune Diseases". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT06318533. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*